Target Information
| Target General Infomation | |||||
|---|---|---|---|---|---|
| Target ID |
T74937
(Former ID: TTDI02054)
|
||||
| Target Name |
Dopamine beta hydroxylase (DBH)
|
||||
| Synonyms |
Soluble dopamine betahydroxylase; Dopamine betamonooxygenase; Dopamine betahydroxylase; Dopamine beta-monooxygenase; Dopamine beta-hydroxylase
|
||||
| Gene Name |
DBH
|
||||
| Target Type |
Clinical trial target
|
[1] | |||
| Disease | [+] 2 Target-related Diseases | + | |||
| 1 | Heart failure [ICD-11: BD10-BD1Z] | ||||
| 2 | Post-traumatic stress disorder [ICD-11: 6B40] | ||||
| Function |
Conversion of dopamine to noradrenaline.
|
||||
| BioChemical Class |
Paired donor oxygen oxidoreductase
|
||||
| UniProt ID | |||||
| EC Number |
EC 1.14.17.1
|
||||
| Sequence |
MPALSRWASLPGPSMREAAFMYSTAVAIFLVILVAALQGSAPRESPLPYHIPLDPEGSLE
LSWNVSYTQEAIHFQLLVRRLKAGVLFGMSDRGELENADLVVLWTDGDTAYFADAWSDQK GQIHLDPQQDYQLLQVQRTPEGLTLLFKRPFGTCDPKDYLIEDGTVHLVYGILEEPFRSL EAINGSGLQMGLQRVQLLKPNIPEPELPSDACTMEVQAPNIQIPSQETTYWCYIKELPKG FSRHHIIKYEPIVTKGNEALVHHMEVFQCAPEMDSVPHFSGPCDSKMKPDRLNYCRHVLA AWALGAKAFYYPEEAGLAFGGPGSSRYLRLEVHYHNPLVIEGRNDSSGIRLYYTAKLRRF NAGIMELGLVYTPVMAIPPRETAFILTGYCTDKCTQLALPPSGIHIFASQLHTHLTGRKV VTVLVRDGREWEIVNQDNHYSPHFQEIRMLKKVVSVHPGDVLITSCTYNTEDRELATVGG FGILEEMCVNYVHYYPQTQLELCKSAVDAGFLQKYFHLINRFNNEDVCTCPQASVSQQFT SVPWNSFNRDVLKALYSFAPISMHCNKSSAVRFQGEWNLQPLPKVISTLEEPTPQCPTSQ GRSPAGPTVVSIGGGKG |
||||
| Drugs and Modes of Action | |||||
| Clinical Trial Drug(s) | [+] 2 Clinical Trial Drugs | + | |||
| 1 | Etamicastat | Drug Info | Phase 2 | Heart failure | [2] |
| 2 | Nepicastat oral | Drug Info | Phase 2 | Post-traumatic stress disorder | [3], [4] |
| Mode of Action | [+] 1 Modes of Action | + | |||
| Inhibitor | [+] 2 Inhibitor drugs | + | |||
| 1 | Etamicastat | Drug Info | [1] | ||
| 2 | Nepicastat oral | Drug Info | [5] | ||
| Target Regulators | |||||
| Target-regulating Transcription Factors | |||||
| Target-interacting Proteins | |||||
| Target Affiliated Biological Pathways | |||||
| BioCyc | [+] 1 BioCyc Pathways | + | |||
| 1 | Catecholamine biosynthesis | ||||
| KEGG Pathway | [+] 2 KEGG Pathways | + | |||
| 1 | Tyrosine metabolism | ||||
| 2 | Metabolic pathways | ||||
| Panther Pathway | [+] 2 Panther Pathways | + | |||
| 1 | Adrenaline and noradrenaline biosynthesis | ||||
| 2 | Dopamine receptor mediated signaling pathway | ||||
| Pathwhiz Pathway | [+] 2 Pathwhiz Pathways | + | |||
| 1 | Catecholamine Biosynthesis | ||||
| 2 | Tyrosine Metabolism | ||||
| WikiPathways | [+] 3 WikiPathways | + | |||
| 1 | Monoamine Transport | ||||
| 2 | Biogenic Amine Synthesis | ||||
| 3 | Metabolism of amino acids and derivatives | ||||
| References | |||||
| REF 1 | Safety, tolerability, and pharmacokinetics of etamicastat, a novel dopamine-beta-hydroxylase inhibitor, in a rising multiple-dose study in young healthy subjects. Drugs R D. 2010;10(4):225-42. | ||||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034724) | ||||
| REF 3 | ClinicalTrials.gov (NCT00641511) Pharmacogenetic Clinical Trial of Nepicastat for Post Traumatic Stress Disorder (PTSD). U.S. National Institutes of Health. | ||||
| REF 4 | ClinicalTrials.gov (NCT01704196) A Multi-Center Trial of Nepicastat for Cocaine Dependence. U.S. National Institutes of Health. | ||||
| REF 5 | Catecholamine modulatory effects of nepicastat (RS-25560-197), a novel, potent and selective inhibitor of dopamine-beta-hydroxylase. Br J Pharmacol. 1997 Aug;121(8):1803-9. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Wang and Dr. Li.